// App-Quantinova.ai

P220 : An updated safety profile of baricitinib for the treatment of RA up to 7 years

Researchers

Presenter

  • David Walker

Principal Investigators

  • Ilias Kouris

  • Thorsten Holzkmper

  • Marco W Wu

  • Ricardo Xavier

  • Josef Smolen

  • Patrick Durez

  • Yi-Hsing Chen

  • Jinglin Zhong

  • Ran Liao

  • Mark C Genovese

  • Kevin Winthrop

Medical Centers

  • Northumbria Healthcare Trust, NHS, Northumbria, UNITED KINGDOM

  • Eli Lilly and Company, Eli Lilly and Company, Indianapolis, IN

  • School of Medicine, Pediatrics, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil

  • Department of Medicine 3, Division of Rheumatology, Vienna, AUSTRIA

  • Service de Rhumatologie (RUMA 5390), Cliniques Universitaires Saint-Luc, Brussels, BELGIUM

  • Division of Allergy Immunology and Rheumatology, Taichung Veterans General Hospital, Tacihung, TAIWAN

  • IQVIA, IQVIA, Rockville, MD

  • Department of Medicine, Standford Healthcare, California, CA

  • School of Medicine, Ponce Health Sciences University, Ponce, PR

Locations

  • United Kingdom

  • United States

  • Brazil

  • Austria

  • Belgium

  • Taiwan

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved